Search for: "CIPLA"
Results 81 - 100
of 202
Sort by Relevance
|
Sort by Date
8 Jan 2011, 2:18 pm
The Application was refused after Bayer failed to overcome the pre-grant oppositions filed against the Application by generic manufacturers Cipla [read post]
21 Sep 2010, 7:47 pm
– Peanut based malnutrition treatment – humanitarian developments and compulsory licensing (IP finance) NGOs warn on IP in Trans Pacific Trade Agreement (IP Watch) Africa: African traditional knowledge and folklore given IP protection despite warning of TK commodification (IP Watch) Brazil, EU, India, Netherlands: Consultations on WTO drug transit case continue (IP Watch) EU: Vaccines causing trouble once more… Georgetown University referral to ECJ concerning SPC Regulation (The… [read post]
15 Sep 2010, 2:40 am
KG v Apotex Pty Ltd (No 2) (Patentology) MoviPrep – US: Salix and Norgine settle with Novel in patent dispute over MoviPrep (Patent Docs) Nexavar (Sorafenib) – India: Nexavar patent infringement suit before Delhi HC goes directly to trial: Bayer v Cipla (Spicy IP) Simcor (Niacin/Simvastatin) – US: Abbott files patent infringement suit against Teva following Para IV challenge (Patent Docs) Vancocin (Vancomycin) – US: ViroPharma sues FDA over generic Vancocin; alleges… [read post]
15 Sep 2010, 1:11 am
Cipla (Sorafenib) litigation.I recommend reading their post, here.Our old posts on Sorafenib, here. [read post]
7 Sep 2010, 6:10 pm
biuras, Amgen Europe BV (The SPC Blog) Aricept (Donepezil) – US: District Court denies Apotex declaratory judgment motion on generic Aricept; does not accept ‘prompt launch’ and ‘indefinite delay’ jurisdiction theories (FDA Law Blog) Chantix (Varenicline) – US: Pfizer files patent infringement complaint against Mylan following Para IV challenge (Patent Docs) (AboutLawsuits.com) Copaxone (Glatiramer) – US: Court denies Sandoz/Momenta’s summary judgment… [read post]
3 Sep 2010, 7:06 am
Cipla and Richter Gedeon were contesting the latter's patent IN206098 (for contraceptive drug Levonorgestrel) at the Mumbai patent office in a post grant opposition proceeding. [read post]
30 Aug 2010, 6:19 am
Continued from our last post where we briefly discussed about the rejection of pre-grant opposition filed by Cipla for the Application Number 3003/CHENP/2004 for anti-cancer drug Nilotinib which later matured into issued Patent Number 237430. [read post]
30 Aug 2010, 6:19 am
Continued from our last post where we briefly discussed about the rejection of pre-grant opposition filed by Cipla for the Application Number 3003/CHENP/2004 for anti-cancer drug Nilotinib which later matured into issued Patent Number 237430. [read post]
25 Aug 2010, 12:37 am
(Patent Docs) (The IP Factor) Dexpramipexole – US: Knopp Neurosciences deal shows how IP strategy can build value for licensing (IP Spotlight) Dulera (Formoterol Fumarate and Mometasone Furoate) – India: Novartis loses Dulera patent in India (Patent Circle) Evoxac (Cevimeline) – US: Daiichi, Apotex reach settlement in Evoxac patent suit (Patent Docs) HPV detection kit – US: Arbitration award to Roche and Gen-Probe approved in HPV license suit with Qiagen (Patent Docs) I-pill… [read post]
19 Aug 2010, 1:33 pm
In another post-grant opposition decided earlier this month, the Mumbai Patent Office revoked Indian Patent Number 202297 issued to Richter Gedon protecting emergency contraceptive pill containing 1.5mg Levonorgestrel, the active ingredient of Cipla’s money spinner i-pill (recently sold to Piramal Healthcare) and Mankind’s Unwanted 72. [read post]
19 Aug 2010, 1:33 pm
In another post-grant opposition decided earlier this month, the Mumbai Patent Office revoked Indian Patent Number 202297 issued to Richter Gedon protecting emergency contraceptive pill containing 1.5mg Levonorgestrel, the active ingredient of Cipla’s money spinner i-pill (recently sold to Piramal Healthcare) and Mankind’s Unwanted 72. [read post]
19 Aug 2010, 12:12 pm
Earlier this month, the Swiss Multinational Novartis lost DULERA post-grant opposition to Mumbai-based Cipla as the Chennai Patent Office revoked Indian Patent Number 202350 on the ground of obviousness/lack of inventive step. [read post]
19 Aug 2010, 12:12 pm
Earlier this month, the Swiss Multinational Novartis lost DULERA post-grant opposition to Mumbai-based Cipla as the Chennai Patent Office revoked Indian Patent Number 202350 on the ground of obviousness/lack of inventive step. [read post]
18 Aug 2010, 12:19 am
Les Laboratoires Servier (No 2) (Patentology) India: Post grant oppositions – new decisions: Richter v Cipla; Novartis v Cipla (Generic Pharmaceuticals and IP) Mexico: COFEMER and AMELAF comment on Biotech Regulations in Mexico (Patent Docs) US: American Bar Association files amicus brief in Therasense case (Patent Docs) US: Biopolymer Engineering and MIT fail to get vacation (of summary judgment): Biopolymer Engineering and MIT v. [read post]
16 Aug 2010, 5:42 am
Friends,On my track of the IPO publishing new decisions, I have found interesting reads in 2 new post grant opposition decisions.The first decision is for a proceeding between Richter and Cipla for contraceptive drugs. [read post]
10 Aug 2010, 8:44 pm
Highlights this week included: CAFC: Genus-species; doctrine of equivalents; and patentable subject matter: Intervet v Merial Limited (Patently-O) (Holman’s Biotech IP Blog) (IP Spotlight) (IPBiz) (Patent Docs) Angiomax (Bivalirudin) – US: The Medicines Company prevails in patent term extension dispute; USPTO acts quickly to comply with court order (Patent Docs) (Patent Docs) (IPBiz) Skelaxin (Metaxalone) – US: CAFC: Ignoring non-patentable elements while judging novelty:… [read post]
4 Aug 2010, 9:11 am
Union of India/ Cipla hearing for the patent linkage matter (earlier blogged here) has been adjourned, at the request of one of the parties.The matter is now likely to be posted for hearing in the last week of November, 2010. [read post]
20 Jul 2010, 12:20 am
Friends from Delhi have the following update:a) The Bayer / Cipla Sorafenib patent infringement suit at the Delhi High Court will be next heard on 23rd July, 2010.b) The Bayer/ Cipla Sorafenib/ Patent linkage case at the Supreme Court will be next heard on 03rd August, 2010.c) The Roche/ Natco Erlotinib infringement suit at the Delhi High Court will be heard on a daily basis, from 27th July, 2010 [read post]
1 Jun 2010, 8:16 am
Ivax and Cipla, sustained trial decision in favor of Forest and Lundbeck to prote [read post]
13 May 2010, 4:58 pm
(Patent Docs) Valcyte (Valganciclovir) - India overturns patent on AIDS patient drug (IP Watch) Viread (Tenofovir) - India: Cipla serves legal notice on GWU; demands a written apology for events in relation to the GWU-CII Summit (Spicy IP) Zetia (Ezetimibe) – US: Three claims of Schering's Zetia patent found invalid(Patent Docs) [read post]
